Aligos Therapeutics develops investigational therapies for liver and viral diseases as a clinical-stage biotechnology company. Its news centers on programs for chronic hepatitis B virus infection, metabolic dysfunction-associated steatohepatitis, obesity, and coronavirus infections, including pevifoscorvir sodium, ALG-055009, ALG-097558, and ALG-170675.
Recurring updates cover clinical and nonclinical data, regulatory designations, scientific-conference presentations, quarterly financial results, research and development spending, licensing agreements, and equity compensation actions. Company releases also describe the Phase 2 B-SUPREME study of pevifoscorvir sodium, FDA Fast Track Designation for chronic HBV infection, and the exclusive license agreement for Greater China with Xiamen Amoytop Biotech.
Aligos Therapeutics (ALGS) reported a narrower third-quarter 2026 net loss while advancing its clinical studies for chronic hepatitis B infection. Net loss was $21.86 million, or $2.09 per share, versus $31.537 million, or $3.04 per share, a year earlier. Research and development expenses fell to $18.892 million from $23.937 million, while general and administrative expenses rose.
Cash, cash equivalents and investments totaled $31.1 million at September 30, versus $77.8 million at December 31, 2025. Aligos expects cash and cash equivalents to fund planned operations into Q1 2027. Phase 2 B-SUPREME enrollment is complete, with 131 participants in the HBeAg-positive cohort and 114 in the HBeAg-negative cohort; topline results are expected in late Q3 2027. Partner Amoytop advanced ALG-170675 into Phase 1 studies in China and is funding current development costs there.
Aligos Therapeutics (ALGS) announced clinical and preclinical liver-disease findings for five presentations at The Liver Meeting 2026 in Denver.
In nine participants, inflammatory cytokine expression fell from baseline after pevifoscorvir sodium treatment, then increased during entecavir-only follow-up. Laboratory studies showed its active parent compound inhibited two hepatitis B virus DNA forms with similar potency, including one associated with viral DNA integration into the host genome.
ALG-170675 reduced hepatitis B surface antigen more than bepirovirsen in a mouse model and has advanced to Phase 1 studies in China with partner Amoytop. ALG-215007 inhibited hepatitis delta virus replication across multiple cellular systems in laboratory testing.
Aligos Therapeutics (Nasdaq: ALGS) announced acceptance of five abstracts for presentation at The Liver Meeting, held November 5–9, 2026, in Denver.
Three abstracts cover pevifoscorvir sodium in chronic hepatitis B, including immune effects, hepatitis B surface antigen levels and laboratory testing. Another covers the preclinical profile of ALG-170675, and the fifth addresses ALG-215007 inhibition of hepatitis delta virus replication. The hepatitis B presentations are scheduled for November 8; the hepatitis delta presentation is scheduled for November 7. The abstracts are available on the AASLD website.
Aligos Therapeutics (ALGS) will present at the Cantor Global Healthcare Conference during a fireside chat scheduled for Wednesday, September 9, 2026, at 8:00 a.m. ET.
The presentation will premiere online at that time and can be accessed via the Presentation & Events section of the Investors page on Aligos’ website. A webcast replay will be available for at least 30 days following the event.
Aligos Therapeutics (Nasdaq: ALGS) announced that its partner Xiamen Amoytop Biotech has dosed the first participant in a Phase 1 study of ALG-170675, an investigational next-generation antisense oligonucleotide for potential functional cure of chronic hepatitis B virus (HBV) infection. Amoytop is conducting the study in China and holds rights in Greater China.
The trial will assess safety, tolerability, pharmacokinetics, and pharmacodynamics using single and multiple ascending doses in healthy participants, followed by a cohort of chronic HBV participants. The design includes single-dose cohorts of 75, 150, 300, and 450 mg, a multiple-dose phase, and a chronic HBV cohort expected to start in Q4 2026. ALG-170675, discovered by Aligos under a collaboration with Amoytop, has associated novel intellectual property and has shown improved RNase H–mediated in vivo activity over GSK‑836 (bepirovirsen) with similar hTLR8 agonist activity in preclinical testing, as well as use of novel monomers intended to potentially reduce toxicity and improve liver-to-kidney distribution.
Aligos Therapeutics (Nasdaq: ALGS) reported second quarter 2026 results and pipeline updates, highlighting progress in its chronic hepatitis B (HBV) programs pevifoscorvir sodium and ALG-170675. Pevifoscorvir sodium received Breakthrough Therapy Designation in China in addition to prior U.S. Fast Track status, and the Phase 2 B-SUPREME study completed enrollment with 131 HBeAg+ and 114 HBeAg- participants. Topline data are expected in late Q3 2027.
According to Aligos, an exclusive Greater China license with Amoytop for pevifoscorvir sodium generated a $25M upfront payment and eligibility for up to $420M in milestones plus tiered high single-digit royalties, while Amoytop’s China IND approval for ALG-170675 triggered a $3M milestone. Q2 2026 net loss narrowed to $1.5M from $15.9M a year earlier, driven by $27.8M licensing revenue and warrant fair-value income, despite higher R&D expenses of $24.1M. Cash, cash equivalents and investments were $30.4M at June 30, 2026, excluding the $25M received in July, and are expected by the company to fund operations through Q4 2026.
Aligos Therapeutics (Nasdaq: ALGS), a clinical stage biotechnology company focused on therapies for liver and viral diseases, announced it will release its second quarter 2026 financial results on Thursday, August 6, 2026, before the U.S. financial markets open.
Aligos emphasizes a science-driven approach and R&D expertise to advance a pipeline addressing high unmet medical needs, including chronic hepatitis B virus (HBV) infection. Investors and stakeholders can find more information at the company’s website or by contacting Investor Relations.
Aligos Therapeutics (Nasdaq: ALGS) announced completion of enrollment in its global Phase 2 B-SUPREME study of pevifoscorvir sodium for chronic hepatitis B virus (HBV) infection. Both HBeAg+ (Part 1a) and HBeAg- (Part 2a) cohorts are now fully enrolled, with topline safety and efficacy data expected in late third quarter 2027.
According to Aligos, Part 1a enrolled 131 HBeAg+ participants, leading to overenrollment before the planned second interim analysis; as a result, the sample size re-estimation interim analysis will not be conducted. Part 2a enrolled 114 HBeAg- participants. The company views this milestone as a key step in advancing pevifoscorvir sodium toward potential registration for chronic HBV.
Aligos Therapeutics (Nasdaq: ALGS) received a $25M upfront payment from an exclusive license deal with Amoytop for pevifoscorvir sodium in Greater China for chronic hepatitis B.
Aligos is eligible for up to $420M in milestones plus tiered royalties, and the drug gained Breakthrough Therapy Designation in China with priority NDA review.
Aligos Therapeutics (Nasdaq:ALGS) reported new clinical and preclinical liver disease data at the EASL Congress 2026 in Barcelona.
Phase 1 follow-up of pevifoscorvir sodium in chronic HBV showed sustained HBV DNA control on NA therapy and HBsAg declines that may enable eligibility for antisense oligonucleotide regimens.
Multiple posters also highlighted ASO ALG-170675, HDV strategies, THR-β agonist ALG-055009 and PD-1/PD-L1 inhibitor ALG-093940.